[Use of electron acceptor compounds in radiotherapy]

Area of Science:

• Oncology
• Radiation Oncology
• Pharmacology

Background:

• Electron acceptor compounds are investigated for their potential as radiosensitizers in tumor radiation therapy.
• Metronidazole, an electron acceptor, has been analyzed for its efficacy and optimal administration in this context.

Purpose of the Study:

• To analyze the prerequisites for using electron acceptor compounds as radiosensitizers.
• To evaluate the short-term results of treating 148 patients with metronidazole.
• To determine the optimal administration route and timing for metronidazole in conjunction with radiation therapy.

Main Methods:

• Analysis of prerequisites for electron acceptor radiosensitizers.
• Clinical trial involving 148 patients treated with metronidazole.
• Pharmacokinetic study of metronidazole distribution in blood and tissues.
• Development of a specialized radiation therapy scheme incorporating metronidazole.

Main Results:

• The combined oral and enema administration (1/3 oral, 2/3 enema) yielded the highest metronidazole levels in tumors.
• Peak drug concentration in tumors was observed 4-6 hours post-administration, coinciding with radiation therapy.
• Short-term therapeutic results showed metronidazole efficacy comparable to or slightly better than the control group.

Conclusions:

• Combined administration of metronidazole is superior for achieving therapeutic concentrations in tumors during radiation therapy.
• Metronidazole demonstrates potential as a radiosensitizer, with specific administration protocols enhancing its effectiveness.
• Further investigation into metronidazole's role in radiation therapy is warranted based on these short-term findings.